Patients at high risk of haemorrhage. Monitor patients receiving anticoagulant therapy & adjust anticoagulant dose, if necessary, due to moderate increase in bleeding time. ALT & AST levels should be monitored in patients w/ any signs of liver damage. Not indicated in exogenous hypertriglyceridaemia (type 1 hyperchylomicronaemia). Limited experience in secondary endogenous hypertriglyceridaemia (especially uncontrolled diabetes); elderly >70 yr; patient w/ renal impairment. No information regarding use in patients w/ hepatic impairment; hypertriglyceridaemia in combination w/ fibrates. Should not be used during pregnancy unless clearly necessary. Should not be used during lactation. Not recommended in childn due to the absence of efficacy & safety data.